Anna Plotka

560 total citations
54 papers, 414 citations indexed

About

Anna Plotka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Anna Plotka has authored 54 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 11 papers in Genetics. Recurrent topics in Anna Plotka's work include Advanced Breast Cancer Therapies (12 papers), Chronic Lymphocytic Leukemia Research (7 papers) and PARP inhibition in cancer therapy (7 papers). Anna Plotka is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), Chronic Lymphocytic Leukemia Research (7 papers) and PARP inhibition in cancer therapy (7 papers). Anna Plotka collaborates with scholars based in United States, United Kingdom and France. Anna Plotka's co-authors include Melissa O’Gorman, Diane Wang, Diane D. Wang, Haihong Shi, Christine Alvey, Virginia Parks, Marci L. Chew, Tanja Alebić-Kolbah, Alain Patat and Joseph M. Scavone and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Anna Plotka

51 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Plotka United States	12	183	104	99	65	63	54	414
Tomoaki Higuchi Japan	13	221 1.2×	52 0.5×	155 1.6×	17 0.3×	105 1.7×	44	526
Gerald M. Higa United States	13	238 1.3×	81 0.8×	168 1.7×	36 0.6×	52 0.8×	50	545
Armin Bruelisauer Switzerland	8	136 0.7×	34 0.3×	120 1.2×	21 0.3×	80 1.3×	10	474
Sheila Shay United States	12	80 0.4×	214 2.1×	110 1.1×	29 0.4×	63 1.0×	35	546
Rita Schröter Germany	13	239 1.3×	73 0.7×	167 1.7×	15 0.2×	132 2.1×	32	529
Vladimir Piotrovsky United States	9	170 0.9×	44 0.4×	199 2.0×	32 0.5×	27 0.4×	12	470
Hisahide Nishio Japan	13	66 0.4×	121 1.2×	154 1.6×	34 0.5×	190 3.0×	29	387
Beate Beer Austria	11	101 0.6×	57 0.5×	72 0.7×	15 0.2×	45 0.7×	22	362
Giulia Ghibellini United States	12	273 1.5×	25 0.2×	71 0.7×	33 0.5×	129 2.0×	17	632
Alessandro Scoppola Italy	14	220 1.2×	85 0.8×	147 1.5×	39 0.6×	21 0.3×	27	556

Countries citing papers authored by Anna Plotka

Since Specialization

Citations

This map shows the geographic impact of Anna Plotka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Plotka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Plotka more than expected).

Fields of papers citing papers by Anna Plotka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Plotka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Plotka. The network helps show where Anna Plotka may publish in the future.

Co-authorship network of co-authors of Anna Plotka

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Plotka. A scholar is included among the top collaborators of Anna Plotka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Plotka. Anna Plotka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

González, Mercedes E., et al.. (2025). A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata. Pediatric Dermatology. 42(4). 742–746. 1 indexed citations

Malhotra, Bimal, et al.. (2025). Advancing Early Clinical Trials: The Transformative Potential of Decentralized Designs and Digital Technologies in Phase 1 Clinical Trial. Clinical Pharmacology & Therapeutics. 118(5). 1143–1151.

Purohit, Vivek S., et al.. (2025). Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450. British Journal of Clinical Pharmacology. 91(8). 2316–2326.

Bauman, Jonathan, Angela C. Doran, Brian Hee, et al.. (2024). The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans. Drug Metabolism and Disposition. 52(10). 1124–1136. 7 indexed citations

Plotka, Anna, Julia Kaplan, Vivek S. Purohit, et al.. (2023). Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity. Pharmaceutical Research. 40(11). 2639–2651. 3 indexed citations

Wang, Xiaoxing, Vivek S. Purohit, Martin E. Dowty, et al.. (2023). Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes. The Journal of Clinical Pharmacology. 63(7). 784–797. 11 indexed citations

Durairaj, Chandrasekar, Jayeta Chakrabarti, Cristiano Ferrario, et al.. (2021). The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. Clinical Pharmacokinetics. 60(7). 921–930. 8 indexed citations

Yu, Yanke, Justin Hoffman, Anna Plotka, et al.. (2020). Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function. Cancer Chemotherapy and Pharmacology. 86(6). 701–710. 10 indexed citations

Hoffman, Justin, Jayeta Chakrabarti, Anna Plotka, et al.. (2019). Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors. Anti-Cancer Drugs. 30(5). 523–532. 8 indexed citations

10.

Bass, Almasa, et al.. (2018). Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial. Health Science Reports. 1(9). e61–e61. 5 indexed citations

11.

Korth‐Bradley, Joan, et al.. (2018). Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A. Clinical and Translational Science. 11(3). 283–288. 3 indexed citations

12.

Ruiz-Garcı́a, Ana, Anna Plotka, Melissa O’Gorman, & Diane D. Wang. (2017). Effect of food on the bioavailability of palbociclib. Cancer Chemotherapy and Pharmacology. 79(3). 527–533. 27 indexed citations

13.

Chew, Marci L., Anna Plotka, Christine Alvey, et al.. (2015). Effect of the Gastrointestinal Prokinetic Agent Erythromycin on the Pharmacokinetics of Pregabalin Controlled-Release in Healthy Individuals: A Phase I, Randomized Crossover Trial. Clinical Drug Investigation. 35(5). 299–305. 4 indexed citations

14.

Chew, Marci L., Anna Plotka, Christine Alvey, et al.. (2014). Pharmacokinetics of Pregabalin Controlled-Release in Healthy Volunteers: Effect of Food in Five Single-Dose, Randomized, Clinical Pharmacology Studies. Clinical Drug Investigation. 34(9). 617–626. 20 indexed citations

15.

Chew, Marci L., Christine Alvey, Anna Plotka, et al.. (2014). Pregabalin Controlled-Release Pharmacokinetics in Healthy Volunteers: Analysis of Four Multiple-Dose Randomized Clinical Pharmacology Studies. Clinical Drug Investigation. 34(9). 627–637. 20 indexed citations

16.

Hoffman, Justin, et al.. (2014). A Phase 1 Open-Label Fixed-Sequence Two-Period Crossover Study of the Effect of Multiple Doses of Tamoxifen on Palbociclib (PD-0332991) Pharmacokinetics in Healthy Male Volunteers. Annals of Oncology. 25. i25–i25. 3 indexed citations

17.

Vourvahis, Manoli, et al.. (2013). The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(5). 564–570. 17 indexed citations

18.

Parks, Virginia, et al.. (2011). Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study. European Neuropsychopharmacology. 22(2). 92–99. 5 indexed citations

19.

Patat, Alain, Virginia Parks, Sangeeta Raje, et al.. (2009). Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. British Journal of Clinical Pharmacology. 67(3). 299–308. 17 indexed citations

20.

Patat, Alain, et al.. (2007). A Positron Emission Tomography Study to Assess Binding of Lecozotan, a Novel 5-Hydroxytryptamine-1A Silent Antagonist, to Brain 5-HT1A Receptors in Healthy Young and Elderly Subjects, and in Patients With Alzheimer's Disease. Clinical Pharmacology & Therapeutics. 83(1). 86–96. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact